Work in the lab of PS has been supported by Canada Research Chairs, Canada Foundation for Innovation, Alberta Prion Research Institute, Alberta InnovatesNovartis, MS Society of Canada, National MS Society, National Institutes of Health, Canadian Institutes for Health Research, the Hopewell M.I.N.D prize, Alzheimers Society, Barford Foundation, Krembil Foundation, and generous philanthropists
Morales GA, Laborde E
Given 40-60% nasal bioavailability compared to 80-95% for injection, equivalent nasal doses would be approximately 400-1000mcg to achieve similar systemic levels
Our experienced practitioners stay abreast of the latest research and adhere to the highest safety standards when recommending off-label peptide therapies
BPC 157 side effects are typically mild and go away on their own as the body adjusts to it
This is standard practice in pharmaceutical compounding but rare in individual research settings